MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia-Reference-Cited by-同舟云学术

MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia

Published:2020-10-22 Issue:8 Volume:4 Page:1301-1312
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Kwak Heechun¹,Lee Sumin²,Jo Seunghyun¹,Kwon Young Eun¹,Kang Hyunju¹,Choi Gahee¹,Jung Myung Eun³,Kwak Mi‐Jeong⁴,Kim Seonghoon⁴,Oh Byung‐Ha⁴,Kim Dong‐Sik⁵,Hwang Sung Ho¹

Affiliation:

1. Department of Research and Early Development GC Pharma Gyeonggi‐do Korea

2. Office of Corporate Strategy GC Pharma Gyeonggi‐do Korea

3. Department of R&D Center GC Pharma Gyeonggi‐do Korea

4. Department of Biological Sciences KAIST Institute for the BioCenturyKorea Advanced Institute of Science and Technology Daejeon Korea

5. MOGAM Institute for Biomedical Research Gyeonggi‐do Korea

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12438

Reference24 articles.

1. Advances and innovations in haemophilia treatment

2. The Haemostatic Role of Tissue Factor Pathway Inhibitor

3. Biology of tissue factor pathway inhibitor

4. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor;Chang JY;Thromb Res,2012

5. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.;Journal of Thrombosis and Haemostasis;2024-09

3. Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?;Expert Opinion on Pharmacotherapy;2024-07-23

4. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives;Biomolecules;2024-07-15

5. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans;The AAPS Journal;2024-07-12